Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus AEROSEB DEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus AEROSEB DEX.
ACLOVATE vs AEROSEB-DEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
2 puffs (100 mcg each) intranasally twice daily
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid